Probiotic Treatment for Depression in Parkinson's Disease (NCT05568498)

Overview

This clinical trial investigates whether probiotic supplementation can improve depression symptoms in Parkinson's disease patients. The study targets the gut-brain axis as a modifiable pathway for neuropsychiatric symptoms in PD. Depression is one of the most common non-motor symptoms in PD, affecting up to 50% of patients, and is often undertreated due to the complexity of managing depression alongside motor symptoms and dopaminergic medications.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT05568498 |
| Phase | Phase 2 |
| Status | Recruiting |
| Intervention | Probiotic blend (Lactobacillus, Bifidobacterium) |
| Dose | Once daily |
| Duration | 12 weeks |
| Sample Size | Approximately 80 participants |
| Primary Endpoint | Change in Beck Depression Inventory (BDI-II) score |

Background

Gut-Brain Axis in PD

The gut-brain axis is increasingly recognized as a key player in PD pathogenesis[@braak2006][@perez2021]. This bidirectional communication system involves neural, endocrine, immune, and metabolic pathways connecting the gastrointestinal tract with the central nervous system. In PD, pathological alpha-synuclein aggregates thought to originate in the gut and propagate via the vagus nerve to the brain, representing one of the earliest events in disease development[@bjorklund2020].

Key aspects of gut-brain axis involvement in PD include:

Overview

This clinical trial investigates whether probiotic supplementation can improve depression symptoms in Parkinson's disease patients. The study targets the gut-brain axis as a modifiable pathway for neuropsychiatric symptoms in PD. Depression is one of the most common non-motor symptoms in PD, affecting up to 50% of patients, and is often undertreated due to the complexity of managing depression alongside motor symptoms and dopaminergic medications.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT05568498 |
| Phase | Phase 2 |
| Status | Recruiting |
| Intervention | Probiotic blend (Lactobacillus, Bifidobacterium) |
| Dose | Once daily |
| Duration | 12 weeks |
| Sample Size | Approximately 80 participants |
| Primary Endpoint | Change in Beck Depression Inventory (BDI-II) score |

Background

Gut-Brain Axis in PD

The gut-brain axis is increasingly recognized as a key player in PD pathogenesis[@braak2006][@perez2021]. This bidirectional communication system involves neural, endocrine, immune, and metabolic pathways connecting the gastrointestinal tract with the central nervous system. In PD, pathological alpha-synuclein aggregates thought to originate in the gut and propagate via the vagus nerve to the brain, representing one of the earliest events in disease development[@bjorklund2020].

Key aspects of gut-brain axis involvement in PD include:

• α-Synuclein propagation: Gut vagus nerve may transmit α-synuclein to brain[@braak2006]
• Neuroinflammation: Gut-derived inflammatory signals cross the blood-brain barrier
• Microbiota alterations: PD patients show distinct gut microbiome signatures[@chen2018]
• Leaky gut: Increased intestinal permeability allows bacterial products to enter circulation
• SCFA deficiency: Short-chain fatty acid production is reduced in PD patients

Depression in PD

Depression affects up to 50% of PD patients and represents one of the most disabling non-motor symptoms[@perez2021]:

• Prevalence: Often precedes motor symptoms by years
• Pathophysiology: Linked to neurotransmitter changes (dopamine, serotonin, norepinephrine)
• Gut connection: Associated with gut dysfunction and microbiome alterations
• Treatment challenges: Standard antidepressants have limited efficacy and can worsen motor symptoms
• Impact: Significantly reduces quality of life and treatment adherence

Probiotic Rationale

Probiotics may help through multiple mechanisms[@Sampson2016][@wallace2017][@sandhu2021]:

The specific strains in this trial (Lactobacillus and Bifidobacterium) have been selected based on preclinical evidence showing benefits in alpha-synuclein models and human studies demonstrating safety in PD populations.

Trial Design

Study Population

Inclusion Criteria

• Parkinson's disease diagnosis (UK Brain Bank criteria)
• Age 40-80 years
• Clinically significant depression (BDI-II score ≥14)
• Stable PD medications for ≥4 weeks
• Able to swallow capsules
• Provide informed consent

• Current antidepressant use (within 4 weeks)
• Probiotic supplement use (within 4 weeks)
• Significant gastrointestinal disorders
• Immunocompromised state
• Severe cognitive impairment (MMSE <24)
• Active hallucinations or psychosis

Endpoints

Primary

• Change in Beck Depression Inventory-II (BDI-II) score at 12 weeks

• Change in Parkinson's Disease Questionnaire-39 (PDQ-39)
• Change in MDS-UPDRS Part 1 (non-motor experiences of daily living)
• Gastrointestinal symptom score (GSRS)
• Fecal microbiome composition
• Inflammatory markers (CRP, IL-6)
• Safety and tolerability assessments

Assessment Schedule

| Visit | Timing | Assessments |
|-------|--------|-------------|
| Screening | Week -2 to 0 | BDI-II, medical history, physical exam |
| Baseline | Week 0 | BDI-II, PDQ-39, MDS-UPDRS, blood draws, stool sample |
| Week 4 | Week 4 | BDI-II, safety assessment |
| Week 8 | Week 8 | BDI-II, PDQ-39, safety assessment |
| Week 12 | Week 12 | All primary and secondary endpoints |
| Follow-up | Week 14 | Safety assessment, adverse event review |

Clinical Translation

Biomarker Connections

Gut Health Markers

• Fecal microbiome composition (alpha and beta diversity)
• Inflammatory markers (CRP, IL-6, TNF-α)
• Gut permeability markers (zonulin, lactulose/mannitol ratio)
• Short-chain fatty acid levels (butyrate, propionate, acetate)
• Fecal calprotectin (intestinal inflammation)

• CSF neurotransmitter metabolites
• Inflammatory markers in cerebrospinal fluid
• α-Synuclein seeding assays (RT-QuIC)
• Neurofilament light chain (NfL)

• Motor symptom severity (MDS-UPDRS Part 3)
• Disease duration and progression
• Levodopa equivalent daily dose
• Sleep quality (PDSS-2)

Mechanistic Pathways

Patient Impact

Potential Benefits

• Non-pharmacological depression management
• Addresses root cause of neuropsychiatric symptoms
• Minimal side effects compared to antidepressants
• May improve motor symptoms secondarily
• Symbiotic relationship with existing PD medications
• Potential for disease-modifying effects beyond mood

• Strain-specific effects not fully characterized
• Long-term maintenance required for sustained benefits
• Variable individual response based on baseline microbiome
• Need for personalized probiotic selection
• Regulatory status varies by jurisdiction
• Limited long-term safety data in PD population

Competitive Landscape

| Agent | Mechanism | Stage | Status |
|-------|-----------|-------|--------|
| Probiotic (NCT05568498) | Gut microbiome modulation | Phase 2 | Recruiting |
| SSRIs | Serotonin reuptake inhibition | Standard of care | Approved |
| DBS | Deep brain stimulation | Approved | Various targets |
| Ketamine | NMDA antagonism | Experimental | Phase 2 |
| Antidepressants + Psychotherapy | Combined approach | Standard | Approved |

Research Context

Supporting Evidence

The trial builds on substantial preclinical and clinical evidence:

Preclinical Studies
-Germ-free mice show increased α-synuclein aggregation[@Sampson2016]

• Probiotic supplementation reduces motor deficits in α-synuclein models
• Fecal microbiota transplantation reverses PD-like symptoms in mouse models

• Altered gut microbiome in PD patients vs. healthy controls[@chen2018]
• Correlation between microbiome composition and non-motor symptoms
• Pilot studies showing probiotic benefits for GI symptoms in PD
• Meta-analyses support probiotic efficacy for depression in general populations[@wallace2017]

Ongoing Research

Multiple trials are investigating gut-brain axis interventions in PD:

• Fecal microbiota transplantation trials
• Prebiotic supplementation studies
• Dietary intervention trials (Mediterranean diet)
• Multi-strain probiotic formulations
• Postbiotic (metabolite) approaches

References